<DOC>
	<DOC>NCT02880618</DOC>
	<brief_summary>The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).</brief_summary>
	<brief_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Has signed an EC approved informed consent form Has been treated with the appropriate heart failure guideline directed therapy Has been implanted with the BAROSTIM NEO System in the past 30 days NYHA III and, LVEF ≤ 35% Bilateral carotid bifurcations located above the level of the mandible Baroreflex failure or autonomic neuropathy Uncontrolled, symptomatic cardiac bradyarrhythmias Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation to be greater than 50% Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Reduced ejection fraction</keyword>
</DOC>